Alteration of the gut fecal microbiome in children living with HIV on antiretroviral therapy in Yaounde, CameroonOriginal paper
Karen Pendergrass is a microbiome researcher specializing in microbiome-targeted interventions (MBTIs). She systematically analyzes scientific literature to identify microbial patterns, develop hypotheses, and validate interventions. As the founder of the Microbiome Signatures Database, she bridges microbiome research with clinical practice. In 2012, based on her own investigative research, she became the first documented case of FMT for Celiac Disease, four years before the first published case study.
Read MoreWhat was studied?
This study examined whether HIV infection alters the gut fecal microbiome in children, and whether any such changes relate to immune status, viral load, and the type of pediatric antiretroviral therapy (ART) regimen used. Researchers characterized gut microbiome structure and function, looking at measures such as alpha diversity (within-sample diversity) and beta diversity (between-sample compositional differences). They also considered factors like prophylactic co-trimoxazole use and ethnicity or geography as potential influences on microbiome composition.
Who was studied?
The study included 87 children living with HIV and 82 non-exposed, HIV-negative children, all from Yaounde, a cosmopolitan city in Cameroon. The HIV-infected children were on antiretroviral therapy, with some receiving ritonavir-boosted protease inhibitor (PI/r)-based regimens and others receiving non-nucleoside reverse-transcriptase inhibitor-based regimens. This design allowed comparison of gut microbiomes across HIV status and across different ART regimen types within the same geographic population.
What were the most important findings?
Children living with HIV had significantly lower alpha diversity and altered beta diversity in their gut microbiome compared to HIV-negative children, and these differences did not appear to be explained by CD4+ T cell count or viral load. The HIV-infected children showed increased levels of Akkermansia and Faecalibacterium genera and decreased levels of Escherichia and other Gamma proteobacteria, among other compositional differences. Ethnicity or geography also appeared to influence gut microbiome composition, and children on PI/r-based ART had microbiome profiles that diverged more from HIV-negative controls than those on non-nucleoside reverse-transcriptase inhibitor-based ART.
What are the greatest implications of this study?
The findings suggest that gut microbiome alterations in children with HIV are shaped not only by the infection itself but also by the specific antiretroviral regimen used, since PI/r-based ART was linked to greater divergence from HIV-negative microbiome profiles. Notably, the increase in Faecalibacterium, a genus known for anti-inflammatory, butyrate-producing commensals, alongside Akkermansia, indicates that HIV-associated microbiome shifts are more complex than a simple loss of beneficial taxa. The authors note that further studies are needed to investigate the role of this altered gut microbiome, pointing to an open area for future research on its functional and clinical significance in children with HIV.